Oscar Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSCR research report →
Range $20 – $49
Price Chart
About the company
Oscar Health, Inc. operates as a health insurance provider across the United States. Its offerings include various health plans such as those for individuals and families, small businesses, and Medicare Advantage options.
- CEO
- Mark Thomas Bertolini
- IPO
- 2021
- Employees
- 2,305
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on OSCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.41B
- P/E
- 9.92
- Fwd P/E
- 10.52
- PEG
- 0.02
- P/S
- 0.41
- P/B
- 3.84
- EV/EBITDA
- 3.29
- Div Yield
- 0.00%
- Gross Margin
- 42.29%
- Op Margin
- 5.33%
- Net Margin
- 4.90%
- ROE
- 49.48%
- ROIC
- 32.54%
Latest fiscal year · YoY change
- Revenue
- $11.70B+27.5%
- Gross Profit
- $1.68B-8.8%
- Op Income
- $-396,357,000
- Net Income
- $-443,151,000-1842.5%
- EPS
- $-1.69-1636.4%
- OCF Growth
- +11.9%
- FCF Growth
- +11.4%
- 52W High
- $38.50
- 52W Low
- $10.69
- 50D MA
- $31.70
- 200D MA
- $24.73
- Beta
- 2.49
- RSI (14)
- 30
- Avg Volume
- 5.28M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Oscar Health posted record third-quarter results and raised full-year 2026 guidance, with management saying the company is on track to deliver strong performance a year ahead of plan.· November 5, 2026
- Revenue rose roughly 70% year over year to $5.1 billion in Q3, with earnings from operations up $307 million to $178 million and adjusted EBITDA up $308 million to $207 million.
- MLR improved 450 basis points year over year to 84%, while SG&A improved 350 basis points to a record-low 14% as technology and AI drove efficiency.
- Oscar ended Q3 with 2.7 million members, up 27% year over year, and is entering open enrollment with a 24% larger footprint across 713 counties.
- Management raised 2026 earnings from operations guidance to $850 million-$950 million and revenue guidance to $19.0 billion-$19.3 billion.
- The company is leaning into 2027 growth with a weighted average rate increase of about 14%, expansion into South Carolina, and new products like RetireEase, HelloMeno and Allstate Health Solutions bundles.
Oscar reported Q3 2026 revenue of $5.1 billion, up roughly 70% year over year. Earnings from operations were $178 million, up $307 million year over year, and adjusted EBITDA was $207 million, up $308 million. Net income in Q3 was $167 million, and MLR improved to 84% from the prior year by 450 basis points; SG&A expense ratio improved 350 basis points to 14%. Through the first 9 months of 2026, net income was approximately $1.2 billion, or $3.59 per diluted share, and earnings from operations were approximately $1.3 billion. The company raised full-year 2026 earnings from operations guidance to $850 million-$950 million, raised revenue guidance to $19.0 billion-$19.3 billion, expects year-end membership of about 2.5 million, and now expects full-year MLR of 80.5%-81.5%, SG&A ratio of 15.1%-15.6%, and risk adjustment as a percentage of premiums of 17%-18%. Management also said adjusted EBITDA should be roughly $110 million higher than earnings from operations.
Mark Bertolini framed 2026 as the strongest year in Oscar Health’s history and said the company is executing ahead of plan across profitability, pricing and growth. He emphasized that Oscar is expanding its addressable market through geographic expansion, new consumer products, and distribution partnerships, while also benefiting from competitor exits and program-integrity changes that he believes will support a larger, more stable ACA market. His tone was confident and upbeat, with a clear message that Oscar is positioning for market-share gains and margin expansion in 2027 and beyond.
Richard Blackley focused on the operating drivers behind the quarter: favorable risk adjustment, disciplined pricing, lower SG&A, and improved fixed-cost leverage. He quantified the quarter with $5.1 billion of revenue, 84% MLR, 14% SG&A ratio, $178 million of operating income, $167 million of net income, and $207 million of adjusted EBITDA, and he noted about $250 million of revenue benefit from updated risk-adjustment data. On the balance sheet, Oscar ended Q3 with about $9 billion of cash and investments, including $360 million at the parent, and insurance subsidiaries had about $2.3 billion of capital and surplus, including $1.4 billion of excess capital. He also said the company remains prudent on reserves and is budgeting for seasonal SG&A and medical-cost step-up in Q4.
Analysts pressed management on SG&A seasonality, Q4 medical-cost expectations, and how much of the 2027 outlook depends on program integrity changes, membership mix, and higher morbidity. Management said the Q3 SG&A outperformance reflected disciplined expense management, AI, and fixed-cost leverage, while Q4 will include seasonal spend tied to open enrollment, risk-adjustment operations, and growth investments. On utilization, management said claims PMPM and MLR step up through the year and expects a normal seasonal increase in Q4, with no major metal-specific anomaly; for 2027, they said the market should be broadly flat, with some membership removed by eligibility checks but offset by new members and competitor exits. They also said the 14% 2027 rate increase mainly reflects trend, market morbidity from program-integrity initiatives, and some margin expansion.
The bull case from this call is that Oscar is executing very well operationally and financially, with strong membership growth, better-than-expected margins, and management seeing results ahead of plan. The company also has multiple growth levers for 2027, including expansion into new states, new products, broker-led distribution through Lucie, and tailwinds from competitor exits and program-integrity measures.
The main risks are that Q4 medical costs and MLR will seasonally step up, membership will fall to about 2.5 million as CMS reviews continue, and management is still cautious on reserves and morbidity. Analysts also highlighted uncertainty around future CMS rules, eligibility checks, and whether enrollment friction or changing subsidies could affect market dynamics and broker productivity.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.7%
- Shares Outstanding
- 259.27M
- Float Shares
- 253.30M
of shares held by institutions
445 13F filers
Buy/sell ratio 0.78. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.32M | ▲ 1.73M |
| Vanguard Group Inc | 20.70M | ▲ 540.85K |
| T. Rowe Price Investment Management, Inc. | 13.04M | ▲ 1.39M |
| D. E. Shaw & Co., Inc. | 12.64M | ▲ 7.16M |
| Vanguard Portfolio Management LLC | 12.05M | ▲ 1.02M |
| Vanguard Capital Management LLC | 11.13M | ▲ 548.64K |
| Fmr LLC | 9.00M | ▲ 4.00M |
| American Century Companies Inc | 8.53M | ▼ 528.24K |
| Geode Capital Management, LLC | 7.10M | ▲ 1.28M |
| Thrive Capital Management, LLC | 6.34M | 0 |
| State Street Corp | 6.10M | ▲ 298.97K |
| Citadel Advisors LLC | 4.23M | ▲ 763.19K |
Held by 420 ETFs
Biggest fund positions in OSCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Taneja Rajat | other | 3,565 |
| Nov 13, 26 | Larsen Eric Jon | other | 3,565 |
| Nov 13, 26 | Cohen Tomer | other | 3,565 |
| Nov 13, 26 | Taneja Rajat | other | 0 |
| Nov 13, 26 | Cohen Tomer | other | 0 |
| Nov 13, 26 | Larsen Eric Jon | other | 0 |
| Oct 8, 26 | Plouffe David | other | 641 |
| Oct 8, 26 | Sankaran Sid | other | 1,472 |
| Oct 8, 26 | Gassen William | other | 698 |
| Sep 18, 26 | WITTMAN VANESSA AMES | sell | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OSCR coverage
Recent articles, reports, and earnings notes.
No research on OSCR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSCR report →OSCR or ZURVY: Which Is the Better Value Stock Right Now?
zacks.com · Nov 20
Hy-Vee Health with Oscar Expands Across Iowa, Into Kansas City and Omaha for 2027 Open Enrollment
businesswire.com · Nov 18
Best Growth Stocks to Buy for November 18th
zacks.com · Nov 18
Oscar Health Expands its Board of Directors with Technology, Healthcare and Product Innovators to Advance Consumer Healthcare
businesswire.com · Nov 16
Best Growth Stocks to Buy for November 16th
zacks.com · Nov 16
Oscar Health, Inc. $OSCR Stock Holdings Cut by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 16
Best Growth Stocks to Buy for November 12th
zacks.com · Nov 12
HealthEx Partners with Oscar Insurance to Bring Members' Medical Records Into the Oscar App
globenewswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.